Cash Rich, Low Price – Ardent Health Stock to Break Out?
We think Ardent Health (ARDT) stock is worth a look: It is growing, producing cash, and available at a significant valuation discount. Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through dividends or buybacks. Either move makes them attractive to the market.
What Is Happening With ARDT
ARDT is down 47% so far this year and is now available at a significant discount to its 3-month, 1-year, and 2-year highs. This can be attributed to escalating professional fees and persistent payor denials in 2025. Q3 2025 accounting adjustments, including a $43 million revenue reduction, also impacted outlook.
The stock may not reflect it yet, but here is what’s going well: Ardent exhibits operational momentum: Q3 2025 admissions grew 5.8%; surgeries rose 1.4%. Urgent care acquisitions are expanding its patient base. Q3 2025 operating cash flow reached $154 million. A low 1.0x net leverage ratio indicates financial strength.
ARDT Has Strong Fundamentals
- How To Earn 8.2% Yield While Waiting to Buy WYNN 30% Cheaper
- What Could Light a Fire Under Costco Wholesale Stock
- The Hidden Dangers Facing Amazon.com Stock
- Momentum Meets Value: Centrus Energy Stock Could Be A Good Buy
- High Margins, 34% Discount: Buy Visa Stock Now
- Could You Be Missing Constellation Brands Stock’s Upside?
- Cash Yield: Ardent Health offers an impressive cash flow yield of 12.4%.
- Growing: Revenue growth of 10.9% over the last twelve months means that the cash pile is going to grow.
- Valuation Discount: ARDT stock is currently trading at 41% below its 3-month high, 47% below its 1-year high, and 56% below its 2-year high.
Below is a quick comparison of ARDT fundamentals with S&P medians.
| ARDT | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Facilities | – |
| Free Cash Flow Yield | 12.4% | 4.0% |
| Revenue Growth LTM | 10.9% | 6.1% |
| Operating Margin LTM | 6.0% | 18.8% |
| PS Ratio | 0.2 | 3.3 |
| PE Ratio | 6.2 | 23.5 |
| Discount vs 3-Month High | -41.0% | -5.1% |
| Discount vs 1-Year High | -47.5% | -9.8% |
| Discount vs 2-Year High | -55.6% | -12.2% |
*LTM: Last Twelve Months
But What About The Risk Involved?
While ARDT stock may be a compelling investment opportunity, it’s always helpful to be aware of a stock’s history of drawdown. ARDT fell 70% in the Dot-Com crash, nearly 65% during the 2008 financial crisis, and about 55% amid the 2022 market sell-off. Even the milder pullbacks in 2018 and early 2020 pushed it down more than 20%. The company looks solid on paper, but these numbers show it’s far from immune when markets turn sour.
Other Stocks Like ARDT
Not ready to act on ARDT? You could consider these alternatives:
We chose these stocks using the following criteria:
- Greater than $2 Bil in market cap
- Positive revenue growth
- High free cash flow yield
- Meaningful discount to 3M, 1Y, and 2Y highs
A portfolio that was built starting 12/31/2016 with stocks that fulfil the criteria above would have performed as follows:
- Average 6-month and 12-month forward returns of 25.7% and 57.9% respectively
- Win rate (percentage of picks returning positive) of >70% for both 6-month and 12-month periods
Smart Investing Begins With Portfolios
Individual picks can be volatile but staying invested is what matters. A diversified portfolio helps you stay the course, capture upside and reduce downside
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.